Interim Report 1 July – 30 September 2021

• Strategy updated to include two products targeting 510(k)-approval
• Published data from first comparative study and first study with 5-year follow-up from Episealer®
• Directed share issue executed, raising SEK 159 million – funding until 2025 secured

”We are currently seeing high activity across the business with several initiatives ongoing within our commercialisation, clinical activities and product development. As already communicated, we experienced certain COVID-19 related effects during the quarter that we cannot disregard, but all in all we are taking important steps in the right direction, as we continuously are adding new customers, geographies, products and data, and we have secured funding until mid-2025”, says Pål Ryfors, CEO Episurf Medical.

Third quarter 2021 compared to 2020, Group

• Gross order intake amounted to SEK 1.6m (1.8).
• Order book amounted to SEK 1.4m (1.6)
• Group net sales SEK 1.5m (1.5)
• Loss for the period amounted to SEK -15.9m (-15.4)
• Earnings per share amounted to SEK -0.07 (-0.08)

First nine months 2021 compared to 2020, Group

• Gross order intake amounted to SEK 5.2m (4.3) an increase of 21%
• Group net sales increased by 46% to SEK 5.1m (3.5)
• Loss for the period amounted to SEK -50.4m (-47.7)
• Earnings per share amounted to SEK -0.23 (-0.32)

Significant events during the third quarter

• Results from prospective multicentre study with 5-7 years’ follow-up of the first Swedish Episealer® Knee patients accepted for publication
• Results from first comparative study with the Episealer® Knee implant were accepted for publication
• Episurf Medical investigates the opportunities for launching an implant for the MTP joint in the US market
• Episurf Medical announced additions to the European sales force and Patrick Jamnik to head US business
• Episurf Medical provided an update on the project Episealer® Patellofemoral System for the US market
• Episealer® Talus: Case report with 5-years’ follow-up data were accepted for publication
• European multicentre study were initiated for 5 years’ follow-up of Episealer® Talus patients

Significant events after the third quarter

• Episurf Medical carries out a directed share issue of SEK 159m. Ilija Batljan enters as new large shareholder

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

Veronica Wallin, CFO, Episurf Medical
Tel:+46 (0) 700 37 48 95
Email: veronica.wallin@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CEST on 29 October 2021.

Tags: